Table 2.

Association of FGF21 levels with UACR and eGFR at baseline using multivariable linear regression analysis (n = 5724)

Biomarkers	Model 1a		Model 2b		Model 3c
	B (95% CI)	P-value	B (95% CI)	P-value	B (95% CI)	P-value
eGFR (mL/min/1.73 m2)
ln-transformed FGF21	−1.88 (−2.25 to −1.50)	<0.001	−0.54 (−0.89 to −0.18)	0.003	−0.54 (−0.89 to −0.18)	0.003
FGF21 quartile
1	Reference		Reference		Reference
2	−1.16 (−2.20 to −0.11)	0.030	−0.08 (−1.02 to 0.86)	0.87	−0.08 (−1.02 to 0.87)	0.87
3	−2.32 (−3.37 to −1.27)	<0.001	−0.53 (−1.50 to 0.44)	0.28	−0.53 (−1.50 to 0.43)	0.28
4	−6.30 (−7.35 to −5.24)	<0.001	−2.62 (−3.63 to −1.61)	<0.001	−2.63 (−3.64 to −1.62)	<0.001
Overall P-value		<0.001		<0.001		<0.001
UACR [ln (mg/g)]
ln-transformed FGF21	0.119 (0.090–0.148)	<0.001	0.032 (0.003–0.060)	0.029	0.032 (0.003–0.061)	0.028
FGF21 quartile
1	Reference		Reference		Reference
2	0.062 (−0.018 to 0.143)	0.13	−0.031 (−0.106 to 0.045)	0.43	−0.030 (−0.106 to 0.045)	0.43
3	0.163 (0.082–0.244)	<0.001	0.030 (−0.047 to 0.108)	0.44	0.031 (−0.047 to 0.108)	0.44
4	0.381 (0.299–0.462)	<0.001	0.133 (0.052–0.214)	0.001	0.134 (0.053–0.215)	0.001
Overall P-value		<0.001		<0.001		<0.001

Data are expressed as regression coefficient (95% CI) in terms of per SD (1.35) increase in ln-transformed FGF21 levels. B, regression coefficients; HDL, high-density lipoprotein.

^aAdjusted for age, sex and race/ethnicity.

^bFurther adjusted for BMI, education, smoking, pack-years of smoking, diabetes, systolic blood pressure, use of antihypertensive medication acting on RAAS, use of other antihypertensive medication, use of lipid-lowering medication, HDL cholesterol, triglycerides (ln-transformed), HOMA2-IR (ln-transformed), homocysteine (ln-transformed), interleukin-6 (ln-transformed), C-reactive protein (ln-transformed) and fibrinogen.

^cFurther adjusted for eGFR for UACR analysis and UACR (ln-transformed) for eGFR analysis.